Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rhumbline Advisers boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 13.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,938 shares of the company’s stock after buying an additional 11,594 shares during the period. Rhumbline Advisers owned approximately 0.13% of Viridian Therapeutics worth $1,916,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Viridian Therapeutics in the 4th quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Viridian Therapeutics in the third quarter worth approximately $149,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Viridian Therapeutics in the third quarter valued at approximately $208,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock valued at $318,000 after buying an additional 2,036 shares during the period. Finally, AlphaCentric Advisors LLC boosted its holdings in shares of Viridian Therapeutics by 20.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock worth $341,000 after buying an additional 2,500 shares in the last quarter.

Viridian Therapeutics Stock Down 7.2 %

Shares of NASDAQ:VRDN opened at $14.41 on Tuesday. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20. The business’s 50 day moving average is $18.10 and its 200 day moving average is $19.70. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -3.34 and a beta of 1.32. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on VRDN shares. TD Cowen started coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating for the company. Royal Bank of Canada lifted their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and set a $38.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.